source
- Gossamer Bio regains rights to lung disease asset from Chiesi after Phase 3 failure, eyes FDA submissionGossamer Bio announced that it has taken back the rights to its inhaled pulmonary hypertension candidate from partner Chiesi after the drug failed to meet its primary endpoint in a Phase 3 trial.…
- Gossamer ends $486M PAH partnership with Chiesi after phase 3 missGossamer Bio announced it is terminating its collaboration and licensing agreement with Italy's Chiesi, regaining worldwide development and commercial rights to its pulmonary arterial hypertension…